Setting back the clock

Adenoviral-mediated gene therapy for lysosomal storage disorders

Dolan Sondhi, Neil R. Hackett, Stephen M. Kaminksy, Ronald Crystal

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Lysosomal storage diseases (LSD) arise from mutations in the genes for lysosomal proteins that degrade and recycle macromolecules (Futerman and van Meer, 2004; Mach, 2002; Vellodi, 2005; Walkley, 2001). The undegraded waste products accumulate over time, resulting in derangement of cell physiology and eventually cell death. It follows, therefore, that delivery and expression of a wild-type copy of the defective gene to the affected cells should be preventive or therapeutic. For the lysosomal storage disorders, the challenges for gene therapy are to deliver the gene to the target tissue and to achieve reduction of lysosomal storage, thus preserving cellular function. Of the various strategies to achieve that goal, replication-deficient adenovirusderived vectors (Ad) are generally thought to be inappropriate because although Ad vectors mediate high levels of production of their transgene, expression is transient over a period of only a few weeks (Hackett and Crystal, 2003; Trapnell and Gorziglia, 1994; Wilson, 1996). This chapter provides a contrary and counterintuitive view, making the case for using Ad vectors to treat the lysosomal storage disorders. We do so by first providing an overview of the production and properties of Ad vectors and then discussing studies in which Ad has been used to treat animal models of lysosomal storage diseases. The intent of this analysis is to critically evaluate the applicability of Ad for the challenges provided by LSD, including the required spatial and temporal pattern of gene expression. We then discuss a novel hypothesis, which we call setting back the clock, which holds that, for some lysosomal storage diseases, transient overexpression of the deficient gene at high levels may be sufficient to completely reverse the storage defect and may give a substantial benefit, especially in diseases where the accumulation of the storage defect is slow.

Original languageEnglish
Title of host publicationLysosomal Storage Disorders
PublisherSpringer US
Pages81-95
Number of pages15
ISBN (Electronic)9780387709093
ISBN (Print)9780387709086
DOIs
Publication statusPublished - 1 Jan 2007
Externally publishedYes

Fingerprint

Lysosomal Storage Diseases
Gene therapy
Genetic Therapy
Clocks
Genes
Waste Products
Cell Physiological Phenomena
Transgenes
Defects
Physiology
Cell death
Cell Death
Macromolecules
Animal Models
Gene expression
Mach number
Gene Expression
Animals
Mutation
Tissue

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sondhi, D., Hackett, N. R., Kaminksy, S. M., & Crystal, R. (2007). Setting back the clock: Adenoviral-mediated gene therapy for lysosomal storage disorders. In Lysosomal Storage Disorders (pp. 81-95). Springer US. https://doi.org/10.1007/978-0-387-70909-3_7

Setting back the clock : Adenoviral-mediated gene therapy for lysosomal storage disorders. / Sondhi, Dolan; Hackett, Neil R.; Kaminksy, Stephen M.; Crystal, Ronald.

Lysosomal Storage Disorders. Springer US, 2007. p. 81-95.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sondhi, D, Hackett, NR, Kaminksy, SM & Crystal, R 2007, Setting back the clock: Adenoviral-mediated gene therapy for lysosomal storage disorders. in Lysosomal Storage Disorders. Springer US, pp. 81-95. https://doi.org/10.1007/978-0-387-70909-3_7
Sondhi D, Hackett NR, Kaminksy SM, Crystal R. Setting back the clock: Adenoviral-mediated gene therapy for lysosomal storage disorders. In Lysosomal Storage Disorders. Springer US. 2007. p. 81-95 https://doi.org/10.1007/978-0-387-70909-3_7
Sondhi, Dolan ; Hackett, Neil R. ; Kaminksy, Stephen M. ; Crystal, Ronald. / Setting back the clock : Adenoviral-mediated gene therapy for lysosomal storage disorders. Lysosomal Storage Disorders. Springer US, 2007. pp. 81-95
@inbook{7b8b70e44ca7405c866e8c96503081ad,
title = "Setting back the clock: Adenoviral-mediated gene therapy for lysosomal storage disorders",
abstract = "Lysosomal storage diseases (LSD) arise from mutations in the genes for lysosomal proteins that degrade and recycle macromolecules (Futerman and van Meer, 2004; Mach, 2002; Vellodi, 2005; Walkley, 2001). The undegraded waste products accumulate over time, resulting in derangement of cell physiology and eventually cell death. It follows, therefore, that delivery and expression of a wild-type copy of the defective gene to the affected cells should be preventive or therapeutic. For the lysosomal storage disorders, the challenges for gene therapy are to deliver the gene to the target tissue and to achieve reduction of lysosomal storage, thus preserving cellular function. Of the various strategies to achieve that goal, replication-deficient adenovirusderived vectors (Ad) are generally thought to be inappropriate because although Ad vectors mediate high levels of production of their transgene, expression is transient over a period of only a few weeks (Hackett and Crystal, 2003; Trapnell and Gorziglia, 1994; Wilson, 1996). This chapter provides a contrary and counterintuitive view, making the case for using Ad vectors to treat the lysosomal storage disorders. We do so by first providing an overview of the production and properties of Ad vectors and then discussing studies in which Ad has been used to treat animal models of lysosomal storage diseases. The intent of this analysis is to critically evaluate the applicability of Ad for the challenges provided by LSD, including the required spatial and temporal pattern of gene expression. We then discuss a novel hypothesis, which we call setting back the clock, which holds that, for some lysosomal storage diseases, transient overexpression of the deficient gene at high levels may be sufficient to completely reverse the storage defect and may give a substantial benefit, especially in diseases where the accumulation of the storage defect is slow.",
author = "Dolan Sondhi and Hackett, {Neil R.} and Kaminksy, {Stephen M.} and Ronald Crystal",
year = "2007",
month = "1",
day = "1",
doi = "10.1007/978-0-387-70909-3_7",
language = "English",
isbn = "9780387709086",
pages = "81--95",
booktitle = "Lysosomal Storage Disorders",
publisher = "Springer US",

}

TY - CHAP

T1 - Setting back the clock

T2 - Adenoviral-mediated gene therapy for lysosomal storage disorders

AU - Sondhi, Dolan

AU - Hackett, Neil R.

AU - Kaminksy, Stephen M.

AU - Crystal, Ronald

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Lysosomal storage diseases (LSD) arise from mutations in the genes for lysosomal proteins that degrade and recycle macromolecules (Futerman and van Meer, 2004; Mach, 2002; Vellodi, 2005; Walkley, 2001). The undegraded waste products accumulate over time, resulting in derangement of cell physiology and eventually cell death. It follows, therefore, that delivery and expression of a wild-type copy of the defective gene to the affected cells should be preventive or therapeutic. For the lysosomal storage disorders, the challenges for gene therapy are to deliver the gene to the target tissue and to achieve reduction of lysosomal storage, thus preserving cellular function. Of the various strategies to achieve that goal, replication-deficient adenovirusderived vectors (Ad) are generally thought to be inappropriate because although Ad vectors mediate high levels of production of their transgene, expression is transient over a period of only a few weeks (Hackett and Crystal, 2003; Trapnell and Gorziglia, 1994; Wilson, 1996). This chapter provides a contrary and counterintuitive view, making the case for using Ad vectors to treat the lysosomal storage disorders. We do so by first providing an overview of the production and properties of Ad vectors and then discussing studies in which Ad has been used to treat animal models of lysosomal storage diseases. The intent of this analysis is to critically evaluate the applicability of Ad for the challenges provided by LSD, including the required spatial and temporal pattern of gene expression. We then discuss a novel hypothesis, which we call setting back the clock, which holds that, for some lysosomal storage diseases, transient overexpression of the deficient gene at high levels may be sufficient to completely reverse the storage defect and may give a substantial benefit, especially in diseases where the accumulation of the storage defect is slow.

AB - Lysosomal storage diseases (LSD) arise from mutations in the genes for lysosomal proteins that degrade and recycle macromolecules (Futerman and van Meer, 2004; Mach, 2002; Vellodi, 2005; Walkley, 2001). The undegraded waste products accumulate over time, resulting in derangement of cell physiology and eventually cell death. It follows, therefore, that delivery and expression of a wild-type copy of the defective gene to the affected cells should be preventive or therapeutic. For the lysosomal storage disorders, the challenges for gene therapy are to deliver the gene to the target tissue and to achieve reduction of lysosomal storage, thus preserving cellular function. Of the various strategies to achieve that goal, replication-deficient adenovirusderived vectors (Ad) are generally thought to be inappropriate because although Ad vectors mediate high levels of production of their transgene, expression is transient over a period of only a few weeks (Hackett and Crystal, 2003; Trapnell and Gorziglia, 1994; Wilson, 1996). This chapter provides a contrary and counterintuitive view, making the case for using Ad vectors to treat the lysosomal storage disorders. We do so by first providing an overview of the production and properties of Ad vectors and then discussing studies in which Ad has been used to treat animal models of lysosomal storage diseases. The intent of this analysis is to critically evaluate the applicability of Ad for the challenges provided by LSD, including the required spatial and temporal pattern of gene expression. We then discuss a novel hypothesis, which we call setting back the clock, which holds that, for some lysosomal storage diseases, transient overexpression of the deficient gene at high levels may be sufficient to completely reverse the storage defect and may give a substantial benefit, especially in diseases where the accumulation of the storage defect is slow.

UR - http://www.scopus.com/inward/record.url?scp=84896707926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896707926&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-70909-3_7

DO - 10.1007/978-0-387-70909-3_7

M3 - Chapter

SN - 9780387709086

SP - 81

EP - 95

BT - Lysosomal Storage Disorders

PB - Springer US

ER -